مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Normal view MARC view ISBD view

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. [electronic resource]

By:
  • Kim, Geoffrey
Contributor(s):
  • McKee, Amy E
  • Ning, Yang-Min
  • Hazarika, Maitreyee
  • Theoret, Marc
  • Johnson, John R
  • Xu, Qiang Casey
  • Tang, Shenghui
  • Sridhara, Rajeshwari
  • Jiang, Xiaoping
  • He, Kun
  • Roscoe, Donna
  • McGuinn, W David
  • Helms, Whitney S
  • Russell, Anne Marie
  • Miksinski, Sarah Pope
  • Zirkelbach, Jeanne Fourie
  • Earp, Justin
  • Liu, Qi
  • Ibrahim, Amna
  • Justice, Robert
  • Pazdur, Richard
Producer: 20150625Description: 4994-5000 p. digitalISSN:
  • 1557-3265
Subject(s):
  • Animals
  • Antineoplastic Agents -- chemistry
  • Clinical Trials as Topic
  • Drug Approval
  • Drug Evaluation, Preclinical
  • Humans
  • Indoles -- chemistry
  • Melanoma -- drug therapy
  • Mutation
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins B-raf -- genetics
  • Sulfonamides -- chemistry
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration
  • Vemurafenib
Online resources:
  • Available from publisher's website
In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 20
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Letter; Review

There are no comments on this title.

Log in to your account to post a comment.

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.

APA

Kim G., McKee A. E., Ning Y., Hazarika M., Theoret M., Johnson J. R., Xu Q. C., Tang S., Sridhara R., Jiang X., He K., Roscoe D., McGuinn W. D., Helms W. S., Russell A. M., Miksinski S. P., Zirkelbach J. F., Earp J., Liu Q., Ibrahim A., Justice R. & Pazdur R. (20150625). FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Kim Geoffrey, McKee Amy E, Ning Yang-Min, Hazarika Maitreyee, Theoret Marc, Johnson John R, Xu Qiang Casey, Tang Shenghui, Sridhara Rajeshwari, Jiang Xiaoping, He Kun, Roscoe Donna, McGuinn W David, Helms Whitney S, Russell Anne Marie, Miksinski Sarah Pope, Zirkelbach Jeanne Fourie, Earp Justin, Liu Qi, Ibrahim Amna, Justice Robert and Pazdur Richard. 20150625. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Kim G., McKee A. E., Ning Y., Hazarika M., Theoret M., Johnson J. R., Xu Q. C., Tang S., Sridhara R., Jiang X., He K., Roscoe D., McGuinn W. D., Helms W. S., Russell A. M., Miksinski S. P., Zirkelbach J. F., Earp J., Liu Q., Ibrahim A., Justice R. and Pazdur R. (20150625). FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Kim Geoffrey, McKee Amy E, Ning Yang-Min, Hazarika Maitreyee, Theoret Marc, Johnson John R, Xu Qiang Casey, Tang Shenghui, Sridhara Rajeshwari, Jiang Xiaoping, He Kun, Roscoe Donna, McGuinn W David, Helms Whitney S, Russell Anne Marie, Miksinski Sarah Pope, Zirkelbach Jeanne Fourie, Earp Justin, Liu Qi, Ibrahim Amna, Justice Robert and Pazdur Richard. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20150625.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site